指南与共识血栓与止血

美国血液学会2019年免疫性血小板减少症指南

American Society of Hematology 2019 guidelines for immune thrombocytopenia.
指南 / 共识 · Blood Adv · 2019-01-01

美国血液学会(ASH)基于GRADE方法制定了成人及儿童免疫性血小板减少症(ITP)管理指南,覆盖新诊断、持续性和慢性且一线治疗无效但无危及生命出血的患者,共达成21条推荐,强调共享决策和避免药物副作用。

要点

  • 指南推荐适用于成人及儿童新诊断、持续性或慢性ITP且无危及生命出血者。
  • 管理策略包括观察、糖皮质激素、IVIG、抗D免疫球蛋白、利妥昔单抗、脾切除和TPO受体激动剂。
  • 缺乏证据支持强推荐,总体倾向于避免药物副作用的策略,并重视共享决策。

核心结论

  • 缺乏证据支持对各种管理方法做出强推荐,总体上倾向于避免药物副作用的策略。

研究设计与样本

  • ASH于2015年成立多学科指南小组,包括8名成人临床专家、5名儿科临床专家、2名ITP方法学专家和2名患者代表。
  • 小组审查ASH 2011指南推荐并确定优先问题,采用GRADE方法(包括证据到决策框架)评估截至2017年5月的证据并形成推荐。

主要发现

  • 小组就21条推荐达成一致,覆盖成人及儿童新诊断、持续性和慢性且一线治疗无效但无危及生命出血的ITP管理。

关键数值与推荐

  • 管理方法包括观察、糖皮质激素、IV免疫球蛋白、抗D免疫球蛋白、利妥昔单抗、脾切除和血小板生成素受体激动剂。
  • 共达成21条推荐,证据评估截止至2017年5月。

临床怎么用

  • 临床决策应注重共享决策,尤其在选择二线治疗时。
  • 优先考虑避免药物副作用的策略。

局限性

  • 缺乏来自随机试验的数据来辅助医生管理患者。
  • 缺乏证据支持对各种管理方法做出强推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite an increase in the number of therapies available to treat patients with immune thrombocytopenia (ITP), there are minimal data from randomized trials to assist physicians with the management of patients. OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the management of ITP. METHODS: In 2015, ASH formed a multidisciplinary guideline panel that included 8 adult clinical experts, 5 pediatric clinical experts, 2 methodologists with expertise in ITP, and 2 patient representatives. The panel was balanced to minimize potential bias from conflicts of interest. The panel reviewed the ASH 2011 guideline recommendations and prioritized questions. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including evidence-to-decision frameworks, to appraise evidence (up to May 2017) and formulate recommendations. RESULTS: The panel agreed on 21 recommendations covering management of ITP in adults and children with newly diagnosed, persistent, and chronic disease refractory to first-line therapy who have non-life-threatening bleeding. Management approaches included: observation, corticosteroids, IV immunoglobulin, anti-D immunoglobulin, rituximab, splenectomy, and thrombopoietin receptor agonists. CONCLUSIONS: There was a lack of evidence to support strong recommendations for various management approaches. In general, strategies that avoided medication side effects were favored. A large focus was placed on shared decision-making, especially with regard to second-line therapy. Future research should apply standard corticosteroid-dosing regimens, report patient-reported outcomes, and include cost-analysis evaluations.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019. PMID: 31794604. doi:10.1182/bloodadvances.2019000966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。